Annual IFPMA Reception on the occasion of the 64th World Health Assembly
16 May 2011
18:30 to 21:00
This event has now passed. To browse our upcoming events click here.
The IFPMA Reception held its annual reception for the World Health Assembly (WHA) on 16 May 2011. The theme of the reception was antimicrobial resistance (AMR) – reflecting the theme of the WHO’s World Health Day on 7 April. Over 100 participants attended, including the US Ambassador and other senior diplomatic figures, plus many WHO and industry representatives.
IFPMA Director General Eduardo Pisani welcomed everyone, reiterating the industry’s pledges in this area: to continue our investment in new antibiotics; to work in partnership with WHO and others on education, prevention innovation, access, financing and capacity-building initiatives; and to support WHO efforts to encourage the appropriate use of medicines. Richard Bergstrom, recently appointed Director General of EFPIA, spoke about the threat AMR posed to us all, of the need for new incentives to invest, and of the challenge of ensuring that these medicines are used in an appropriate way. Dr Keiji Fukuda, Assistant Director General at the WHO with responsibility for AMR, talked about the WHO’s efforts to build on World Health Day, working through its regional offices.
Mr Pisani became Director General of the IFPMA at the end of 2009. He came to the IFPMA from Bristol-Myers Squibb, a company he joined in 2001, and in which he had risen to the position of Vice-President, International Policy and Government Affairs. During his time at BMS, Mr Pisani contributed to the development of policy initiatives at a European level in major disease areas like infectious diseases and mental health, as well as to industry work on the value of medicines. He also established the first cross-sectoral industry advocacy group on healthcare policy in Brussels, under the aegis of the American Chamber of Commerce to the EU.
Prior to that, Mr Pisani held positions as legal counsel at Immuno AG in Belgium and Austria, at Baxter Healthcare in Belgium and Italy, and in European Policy and Government Affairs at Adamson Associates and SmithKline Beecham in Belgium. He started his career in 1989, in the marketing department of Lederle France
Richard Bergström has been the Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) since April 2011. Previously he served for nine years as the Director-General of LIF, the Swedish Association of the Pharmaceutical Industry, following positions in Switzerland in regulatory affairs at the pharmaceutical companies Roche and Novartis. Mr Bergström has also been appointed by the Swedish Government to the Board of the Karolinska Institute. He is a pharmacist by training, receiving his MScPharm degree from the University of Uppsala, Sweden in 1988.
Dr Keiji Fukuda has been the Assistant Director-General for Health Security and Environment since 1 September 2010.
He was Special Adviser on Pandemic Influenza to the Director-General from October 2009 to August 2010. Prior to that, he was the Assistant Director-General for Health Security and Environment ad interim. In 2005, he came to WHO as a scientist in the Global Influenza Programme, then was Coordinator from 2006 to 2008 and before being appointed its Director. Under his guidance, the Programme greatly expanded its global role in providing technical leadership and guidance related to seasonal, avian and pandemic influenza.
Dr Fukuda has extensive public health and research experience working on influenza. At WHO, he has helped shape the global approach to pandemic preparedness, helped manage the response to the influenza H1N1 pandemic, strengthened surveillance, and played an instrumental role in facilitating intergovernmental discussions over the sharing of influenza viruses and related benefits. He has participated in many field investigations including the earliest outbreaks of avian H5N1 influenza and the emergence of SARS.
Before coming to WHO, Dr Fukuda was Chief of the Epidemiology Unit, Influenza Branch at the Centers for Disease Control and Prevention in the United States. He is a physician and received his BA from Oberlin College, MD from the University of Vermont and MPH from the University of California, Berkeley.